[March] Dr Agarwal Health Care Share Price Target 2025, 2026, 2027 to 2050 | IPO Info
Dr Agarwal Health Care was founded in 2010 and has quickly grown in India and several African countries, becoming an important name in eye care.
The company offers a range of services, including eye surgeries, consultations, and eye care products.
Its main source of income comes from surgeries, and the company has grown fast in recent years.
This growth is mainly due to the rising need for quality eye care in both India and Africa.
As the demand for better healthcare in these areas continues to grow, the company is well-placed to capture more market share.
Its focus on innovation, patient care, and making services accessible helps it stand out, ensuring continued success in the healthcare field.
With a strong reputation and wider reach, Dr. Agarwal’s Health Care is set to lead in changing eye care services worldwide.
About Dr Agarwal Health Care Company
Dr. Agarwal’s Health Care was founded in 2010 by Dr. J. Agarwal in Chennai, Tamil Nadu, with a focus on providing excellent eye care services.
It initially specialized in treating conditions like cataracts, glaucoma, and refractive errors.
The hospital quickly became known for its high-quality care.
Over time, Dr. Agarwal’s Health Care expanded its services to include various medical specialties to meet the needs of a wider range of patients.
Today, the network has grown to many cities across India and beyond, becoming a trusted name in healthcare.
Known for using advanced medical technology and having skilled doctors, the hospital puts patients first.
It works to make healthcare more affordable and accessible to a larger number of people, ensuring many benefit from its top-quality services.
The hospital’s dedication to innovation and excellent care has made it a leader in the healthcare field.
Dr Agarwal Health Care IPO Details
The IPO for this company will be open from January 29, 2025, to January 31, 2025, with shares listed on the BSE and NSE.
To invest, you need at least ₹13,370.00.
Each share is priced between ₹382 and ₹402, and you need to buy in lots of 35 shares.
The total issue size is 7,53,04,970 shares, aiming to raise to ₹3,027.26 crore.
This includes a new issue of 74,62,686 shares worth ₹300 crore and a sale of 6,78,42,284 shares worth ₹2,727.26 crore.
The IPO is a book-built issue, and shares will be listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
Before the issue, there were 30,84,17,160 shares, and after the issue, this number will increase to 31,58,79,846 shares.
This IPO presents a good chance for investors, as the company’s strong growth and financial health are attracting interest in the market.
Dr Agarwal Health Care Share Earning Results
From March 2020 to March 2024, the company’s performance changed a lot.
In March 2020, sales were 176, but they grew to 319 by March 2024.
Expenses also went up, from 129 in March 2020 to 227 in March 2024.
Operating profit varied, starting at 47 in March 2020 and reaching 92 in March 2024.
The Operating Profit Margin (OPM) ranged from 22% to 29%.
Other income stayed low, going from 3 in March 2020 to 5 in March 2024.
Interest stayed the same at 7-9 during these years, while depreciation went up from 21 to 27.
Profit before tax grew, from 20 in March 2020 to 62 in March 2024.
The tax rate changed, reaching a high of 125% in March 2021 and ending at 26% in March 2024.
Net profit went from a loss of -1 in March 2021 to a gain of 46 in March 2024.
Earnings per share (EPS) also grew a lot, from 29.11 in March 2020 to 98.64 in March 2024.
The dividend payout stayed low, peaking at 6% in March 2022 and falling to 3% in March 2024.
This data shows that the company improved steadily, even though it faced a loss in 2021.
Over the five years, the company kept making profits, which is clear from the growth in net profit and EPS.
Even though expenses went up, the company made more money, leading to a stronger overall financial performance.
These trends suggest that the company’s financial health is getting better, making it a stronger investment in recent years.
Also, check the Vishal Mega Mart Share Price Target 2025 to 2060.
Dr Agarwal Health Care Share GMP(Latest)
| Date | IPO GMP | Kostak |
|---|---|---|
| 30 January | – | – |
| 29 January | – | – |
| 28 January | – | – |
| 27 January | – | – |
Also, check the Coal India Share Price Target 2025 to 2050.
Dr Agarwal Health Care Share Price Target 2025
The company is growing steadily by improving its medical services.
It has treated over 21 lakh patients and performed more than 2.2 lakh pulse surgeries in the past year, making it a well-known name in eye care.
This strong performance is likely to attract more investors, especially as a big part of its earnings comes from surgeries.
With more happy patients and a focus on quality care, the company’s market value is expected to rise.
Its use of advanced treatments and modern technology also helps build trust in the healthcare industry.
Experts believe that by 2025, the company’s stock price could go up to ₹595, with a possible range between ₹355 and ₹595, showing strong growth and investor confidence.
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹355 | ₹595 |
Also, check the Urja Global Share Price Target 2024 to 2050.
Dr Agarwal Health Care Share Price Target 2026
This company has a strong presence in India, with over 193 centers in 117 cities.
It is focused on growth and making eye care more accessible.
To achieve this, it is expanding its Centers of Excellence, which offer advanced surgeries and training programs.
This helps the company grow while also meeting the increasing demand for eye care, especially in smaller cities with fewer medical facilities.
Its smart expansion strategy allows it to reach new areas quickly and effectively.
As medical technology improves and the number of elderly people grows, the need for specialized treatments is increasing.
The company’s innovative approach puts it in a good position for long-term success.
Based on our study, its stock price target for 2026 is expected to be ₹769, with a possible range between ₹534 and ₹769, showing strong potential for future growth.
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹534 | ₹769 |
Also, check the Mishtann Foods Share Price Target 2025 to 2050.
Dr Agarwal Health Care Share Price Target 2027
The company is growing steadily by expanding its business and acquiring other companies.
This helps it reach more customers and gain a larger share of the market.
By improving its infrastructure and operations, the company can increase its revenue and work more efficiently, which may lead to a rise in its stock price.
It also has a strong reputation and experienced medical experts guiding it, making it a good option for investors looking for long-term growth.
As the company becomes more competitive, investor confidence may grow, further boosting its stock performance.
If this growth continues, our analysis suggests that the stock price could reach ₹921 in 2027, with an expected range between ₹741 and ₹921 based on market trends.
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹741 | ₹921 |
Also, Check out NHPC Share Price Target From 2024 to 2050.
Dr Agarwal Health Care Share Price Target 2028
India’s eye care market is expected to grow significantly in the coming years, putting the company in a strong position to take advantage of this growth.
The company’s focus on expanding into emerging markets, especially in Africa, fits well with the growing need for good healthcare services in these areas.
By increasing its presence globally, the company is improving its chances for long-term success.
Its strong financial performance in recent years has also boosted investor confidence, making it a good option for potential investors.
With a clear plan for growth and a strong market presence, the company’s stock price is expected to rise.
Our analysis suggests that by 2028, the stock could reach a price of ₹1,092, with a trading range between ₹879 and ₹1,092, making it an appealing investment opportunity.
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹879 | ₹1092 |
Also, Check the MRPL Share Price Target 2025 to 2050.
Dr Agarwal Health Care Share Price Target 2029
The company is investing a lot in areas like employee training, new technology, and advanced surgeries such as robotic cataract surgery.
These efforts are expected to improve its reputation for excellent eye care.
As the demand for eye care in India grows, the company’s increasing number of patients and growth plans are set to lead to steady revenue increases.
With a stronger financial position, the company’s stock price is likely to rise.
By 2029, we predict the stock price could reach ₹1298, with an expected range between ₹1059 and ₹1298.
This growth shows the company’s success and the overall trend of more people getting access to eye care, making the company an important part of India’s growing healthcare market.
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹1059 | ₹1298 |
Also, check the Jio Financial Services Share Price Target 2024 to 2060.
Dr Agarwal Health Care Share Price Target 2030
As more hospitals and medical centers open, especially in growing markets, the company is set for strong long-term growth.
By focusing on new surgical treatments and keeping patients happy, the company is on track for steady increases in both revenue and stock price.
With more people needing eye care in India and its expanding presence worldwide, the company is becoming a leader in the industry, which should help its stock price rise.
Our analysis shows that by 2030, the stock price could reach ₹1574, with a possible range between ₹1259 and ₹1574.
This growth reflects the company’s ability to meet the growing healthcare demand globally, while also taking advantage of new market opportunities for long-term success.
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹1259 | ₹1574 |
Dr Agarwal Health Care Share Price Target 2035
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹1921 | ₹2010 |
Also, Check RattanIndia Power Share Price Target 2025 to 2050.
Dr Agarwal Health Care Share Price Target 2040
This company is set to stay a leader in the global eye care industry because of its strong ability to grow in fast-developing markets and its continued success in innovative surgical treatments.
With a focus on reaching areas with less access to eye care, both in India and around the world, the company is well-placed for steady growth, which should positively impact its stock value in the long run.
Its flexible business model and commitment to better patient care will help it stay on top of the industry, making it a good choice for long-term investors.
Our analysis suggests that by 2040, the stock price could reach ₹3419, with a range of ₹2975 to ₹3419, showing its strength and growth potential.
By taking advantage of new trends and focusing on technology, the company will continue to grow and offer stable returns for shareholders.
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹2975 | ₹3419 |
Also, check the Stallion India Share Price Target 2025 to 2050.
Dr Agarwal Health Care Share Price Target 2050
The company is on track to become a well-known brand around the world, with a strong presence in both developed and growing markets.
By focusing on expanding into areas with limited access to eye care and investing in advanced eye care technologies, it stands out from its competitors.
As the need for eye care grows, the company’s continued progress is likely to push its stock price higher.
With strong leadership and a good reputation in the industry, investors can expect good returns.
Looking towards 2050, our analysis suggests the stock price could range from ₹4849 to ₹5639, showing the company’s strong future outlook.
Its focus on innovation, expanding reach, and tackling global eye care issues make
it is a great long-term investment.
| Year | Min. Prices | Max. Prices |
|---|---|---|
| 2025 | ₹4849 | ₹5639 |
Also, check the Adani Wilmar Share Price Target 2024 to 2050.
Should I Buy Dr Agarwal Health Care Share? (Bull and Bear Case)
| Bull Case | Bear Case |
|---|---|
| In the past five years, the company has seen a strong 31.4% growth in profits, showing its solid financial performance and strong position in the market. | The stock is currently priced at 15.4 times its book value, which might mean it is too expensive. |
| Its return on equity (ROE) has also been impressive at 36.1% over the last three years, showing that the company is managing well and providing good value to its shareholders. | This high price raises doubts about whether it can stay at this level for a long time. |
| The brand is trusted and has built a strong presence not only in India but also in the growing markets of Africa. | There are also concerns about the company’s financial clarity, which could make investors uneasy. |
| This growth is supported by investments in advanced medical technologies, like robotic cataract surgery, which places the company at the forefront of healthcare innovation. | A major issue is that the promoters have pledged 55.4% of their shares, creating a big financial risk. |
| These efforts are helping the company continue to succeed and expand, making it a leader in both healthcare and business growth. | This could lead to problems if the stock price drops. |
| The company is focused on meeting the changing needs of its customers and staying competitive in the global market. | Because of these risks, investors should carefully check the company’s financial strength before making any decisions. |
Also, check Ajax Engineering IPO Share Price Target 2025 to 2050.
Conclusion
This company is expanding in India and Africa and investing in new technology, which shows good growth potential.
Its plans look strong for long-term success.
However, investors should be careful because the stock seems expensive, and there are concerns about financial transparency and pledged shares by the promoters.
It could be a good option for long-term investors, but it’s important to research before investing.
Understanding the company’s financial health, market trends, and risks can help make better decisions.
Investors should also consider the overall economy and challenges in the industry.
Keeping track of company reports, earnings, and expert opinions can help decide if this stock matches personal investment goals.
8 Comments